Last reviewed · How we verify
Meningeal Leukemia
Approved treatments
- Cytarabine · Nippon Shinyaku Co., Ltd.
Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase. - Trexall · Generic (originally Lederle Laboratories)
Antifolate that inhibits dihydrofolate reductase (DHFR), blocking DNA synthesis at high doses (oncology) and suppressing inflammation at low doses (autoimmune). - Methotrexat · Biocad
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Meningeal Leukemia patent landscape — cliff calendar, originator estates, attackable patents
- Meningeal Leukemia treatment landscape brief
- Meningeal Leukemia treatment updates RSS
Frequently asked questions about Meningeal Leukemia
What drugs treat Meningeal Leukemia?
Tracked treatments include Cytarabine, Trexall, Methotrexat.
What is the treatment for Meningeal Leukemia?
Standard treatment for Meningeal Leukemia includes Cytarabine, Trexall, Methotrexat. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Meningeal Leukemia patent cliff · Meningeal Leukemia CI report
- Treatment: Cytarabine · Nippon Shinyaku Co., Ltd.
- Treatment: Trexall · Generic (originally Lederle Laboratories)
- Treatment: Methotrexat · Biocad
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing